Shopping Cart
Remove All
Your shopping cart is currently empty
Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | In Stock | In Stock | |
| 5 mg | $278 | In Stock | In Stock | |
| 10 mg | $446 | In Stock | In Stock | |
| 25 mg | $787 | In Stock | In Stock | |
| 50 mg | $1,060 | In Stock | In Stock | |
| 100 mg | $1,430 | In Stock | In Stock | |
| 200 mg | $1,930 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $427 | In Stock | In Stock |
| Description | Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. |
| Targets&IC50 | PD-1/PD-L1 (human):0.213 nM (IC50) |
| In vitro | Evixapodlin exhibits an ability to increase the production of IFN-γ and Granzyme B in both CD8+ and CD4+ T cells in individuals with chronic hepatitis B (CHB). Additionally, Evixapodlin enhances the frequency of Granzyme B-positive cells among HBV-specific CD8+ and CD4+ T cells.[1] |
| In vivo | Evixapodlin (10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment results in over 90% occupancy of the PD-L1 target on tumor cells. Evixapodlin effectively suppresses tumor growth in a mouse colorectal tumor model (MC38) that expresses human PD-L1.[1] |
| Synonyms | PD-1/PD-L1-IN 7, GS-4224 |
| Molecular Weight | 691.61 |
| Formula | C34H36Cl2N8O4 |
| Cas No. | 2374856-75-2 |
| Smiles | COc1nc(cnc1CNC[C@@H]1CCC(=O)N1)-c1cccc(c1Cl)-c1cccc(c1Cl)-c1cnc(CNC[C@@H]2CCC(=O)N2)c(OC)n1 |
| Relative Density. | 1.310 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (65.07 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.89 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.